Akebia Therapeutics (AKBA) has provided an announcement.
Akebia Therapeutics and CSL Vifor have mutually terminated their exclusive licensing agreement for the sale of Vafseo in the U.S., ending the partnership for business reasons. Akebia Therapeutics will repay CSL Vifor’s $40 million contribution to a working capital fund through tiered quarterly royalty payments based on net sales, with minimum amounts guaranteed by specific dates up to May 2028. Additionally, the company will make decreasing tiered royalty payments to CSL Vifor from the first sale of Vafseo until the end of the drug’s market exclusivity, with an option to reduce these payments from 2027 onwards.
Learn more about AKBA stock on TipRanks’ Stock Analysis page.
